Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone

Daniel DeAngelo • 10 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia Asciminib Dasatinib Prednisone

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase 1 study (NCT02081378) of asciminib plus dasatinib and prednisone for untreated BCR-ABL1 positive acute lymphoblastic leukemia (ALL) in older adults. Dual ABL1 kinase inhibition with these agents was promising, and an expansion cohort is planned to further characterize safety and clinical activity of the combination. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals